Pascal and Francis Bibliographic Databases


Search results

Your search

kw.\*:("Antiparkinson agent")


A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV


A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 5764

  • Page / 231

Selection :

  • and

Pergolide in the treatment of Parkinson's diseaseMEAR, J.-Y; BARROCHE, G; DE SMET, Y et al.Neurology. 1984, Vol 34, Num 7, pp 983-986, issn 0028-3878Article

In vivo and in vitro evidence of dopaminergic system down regulation induced by chronic L-dopaPONZIO, F; CIMINO, M; ACHILLI, G et al.Life sciences (1973). 1984, Vol 34, Num 22, pp 2107-2116, issn 0024-3205Article

Determination of the enantiomeric purity of levodopa, methyldopa, carbidopa and tryptophan by use of chiral mobile phase high-performance liquid chromatographyGELBER, L. R; NEUMEYER, J. L.Journal of chromatography. 1983, Vol 257, Num 2, pp 317-326, issn 0021-9673Article

Simple and rapid micromethod for the determination of levodopa and 3-O-methyldopa in human plasma by high-performance liquid chromatography with coulometric detectionBARUZZI, A; CONTIN, M; ALBANI, F et al.Journal of chromatography. 1986, Vol 375, Num 1, pp 165-169, issn 0021-9673Article

High-performance liquid chromatographic determination of amantadine in urine after micelle-mediated pre-column derivatization with 1-fluoro-2,4-dinitrobenzeneVAN DER HORST, F. A. L; TEEUWSEN, J; HOLTHUIS, J. J. M et al.Journal of pharmaceutical and biomedical analysis. 1990, Vol 8, Num 8-12, pp 799-804, issn 0731-7085, 6 p.Conference Paper

Carbidopa dosage modifies L-DOPA induced side effects and blood levels of L-DOPA and other aminoacids in advanced parkinsonismPAREJA, F. B; MARTINEZ-MARTIN, P; MURADAS, V et al.Acta neurologica scandinavica. 1985, Vol 72, Num 5, pp 506-511, issn 0001-6314Article

Antiparkinsoniens = Antiparkinson drugsRONDOT, P; DE RECONDO, J; MONTASTRUC, J. L et al.La Semaine des hôpitaux de Paris. 1984, Vol 60, Num 40, pp 2817-2846, issn 0037-1777Article

Comparison of the stimulatory effects of eight antiparkinsonian drugsGOLDSCHMIDT, P. L; SAVARY, L; SIMON, P et al.Progress in neuro-psychopharmacology & biological psychiatry. 1984, Vol 8, Num 2, pp 257-261, issn 0278-5846Article

Sevrage aux antiparkinsoniens non dopaminergiquea = Withdrawal of non dopaminergic antiparkinson drugsLE BELLEC, M; GEORGIE, V.Journal de toxicologie clinique et expérimentale. 1985, Vol 5, Num 1, pp 47-53, issn 0753-2830Article

More on ciladopa. ReplySNIDER, S. R; AMINOFF, M. J; GOODIN, D. S et al.Annals of neurology. 1987, Vol 22, Num 4, issn 0364-5134, 558Article

Bromocriptine: problems with low-dose de novo therapy in Parkinson's diseaseGRIMES, J. D; DELGADO, M. R.Clinical neuropharmacology. 1985, Vol 8, Num 1, pp 73-77, issn 0362-5664Article

Metabolism of carbidopa to alpha-methyldopamine and alpha-methylnorepinephrine in ratsSHELTON, R. C; FAROUK KAROUM; LIN-WHEI CHUANG et al.Biochemical pharmacology. 1985, Vol 34, Num 20, pp 3623-3626, issn 0006-2952Article

Biperiden effects and plasma levels in volunteersHOLLMANN, M; BRODE, E; GREGER, G et al.European journal of clinical pharmacology. 1984, Vol 27, Num 5, pp 619-621, issn 0031-6970Article

Levodopa dependence : a case reportPRIEBE, S.Pharmacopsychiatria. 1984, Vol 17, Num 4, pp 109-110, issn 0720-4280Article

Severity of Parkinsońs disease and the dosage of bromocriptineLARSEN, T. A; NEWMAN, R; LEWITT, P et al.Neurology. 1984, Vol 34, Num 6, pp 795-797, issn 0028-3878Article

Traitement de la maladie de Parkinson = Parkinson disease treatmentGUILLARD, A.Concours médical (Paris). 1986, Vol 108, Num 26, pp 2173-2178, issn 0010-5309Article

Fatal hyperpyrexia after withdrawal of levodopaSECHI, G. P; TANDA, F; MUTANI, R et al.Neurology. 1984, Vol 34, Num 2, pp 249-251, issn 0028-3878Article

Bupropion in Parkinsońs diseaseGOETZ, C. G; TANNER, C. M; KLAWANS, H. L et al.Neurology. 1984, Vol 34, Num 8, pp 1092-1094, issn 0028-3878Article

L-dopa long-term treatment in Parkinson's disease: age-related side effectsPEDERZOLI, M; GIROTTI, F; SCIGLIANO, G et al.Neurology. 1983, Vol 33, Num 11, pp 1518-1522, issn 0028-3878Article

Spectrophotometric method for the determination of carbidopa using neotetrazolium chlorideISSOPOULOS, P. B; ECONOMOU, P. T.Journal of pharmacy and pharmacology. 1992, Vol 44, Num 12, pp 1020-1022, issn 0022-3573Article

Haemodynamic effects of bromocriptine in the conscious spontaneously hypertensive ratSTRUYKER-BOUDIER, H. A. J; VAN ESSEN, H; SMITS, J. F. M et al.Journal of pharmacy and pharmacology. 1984, Vol 36, Num 2, pp 123-125, issn 0022-3573Article

Mazindol in the treatment of Parkinson's diseaseDELWAIDE, P. J; MARTINELLI, P; SCHOENEN, J et al.Archives of neurology (Chicago). 1983, Vol 40, Num 13, pp 788-790, issn 0003-9942Article

L-Dopa Therapie des Parkinsonsyndroms = L-dopa dans le traitement de la maladie de Parkinson = L-dopa treatment of parkinsonismKAPFHAMMER, H.-P; KUB, H. J; RUTHER, E et al.Nervenarzt. 1985, Vol 56, Num 2, pp 57-68, issn 0028-2804Article

Effect of various neuroactive drugs on bromocriptine concentration in the striatum of ratsVARDI, J; GRAFF, E; OBERMAN, Z et al.Israel journal of medical sciences. 1984, Vol 20, Num 5, pp 407-409, issn 0021-2180Article

Accidents de sevrage médicamenteux antiparkinsoniens et neuroleptiques = Antiparkinsonian and neuroleptic drugs: withdrawal complicationsMIZON, J. P; ROSA, A.Thérapie (Paris). 1984, Vol 39, Num 4, pp 421-425, issn 0040-5957Article

  • Page / 231